Illumina Announces Agreement to Acquire GRAIL for USD 8 Billion | Financial Buzz

Illumina Announces Agreement to Acquire GRAIL for USD 8 Billion

Illumina, Inc. (NASDAQ: ILMN) and GRAIL has entered into a definitive agreement where Illumina will acquire GRAIL for cash and stock consideration of USD 8 Billion upon close of the transaction.  GRAIL stockholders will receive future payments that represent a single digit percentage of certain GRAIL-related revenues.  The agreement has been approved by the Board of both companies. 

“Over the last four years, GRAIL’s talented team has made exceptional progress in developing the technology and clinical data required to launch the GalleriTM multi-cancer screening test. Galleri is among the most promising new tools in the fight against cancer, and we are thrilled to welcome GRAIL back to Illumina to help transform cancer care using genomics and our NGS platform,” said Francis deSouza, Illumina’s President and Chief Executive Officer. “Together, we have an important opportunity to introduce routine and broadly available blood-based screening that enables early cancer detection when treatment can be more effective and less costly. Multi-cancer early detection is better for patients, their physicians, and payors. As we accelerate our path to clinical leadership and the path to multi-cancer early detection, we will continue to drive significant value creation for our stockholders.”

“Cancer is one of society’s most significant challenges, with most cancer being detected too late,” said Hans Bishop, Chief Executive Officer of GRAIL. “We believe multi-cancer early detection technology could address a tremendous unmet need and reduce the cancer burden worldwide. Combining forces with Illumina enables broader and faster adoption of GRAIL’s innovative, multi-cancer early detection blood test, enhancing patient access and expanding global reach. We are excited about this next step in our journey to transform cancer detection and outcomes and create value for patients and their families and communities, health care providers and payors, employers, and stockholders.”